Efficacy of IV Valproic Acid and Oral Valproic Acid Tapers for the Treatment of Pediatric Headaches in the Emergency Department

被引:1
|
作者
Rosenthal, Scott [1 ]
Mazzio, Emma [1 ]
Gilbert, Hannah Wellman [1 ]
Guistolisi, Sarah [1 ]
Marks, Jill [1 ]
Jewell, Jerry [1 ]
Straley, Megan [2 ]
Silveira, Lori [2 ]
Messer, Ricka [1 ]
Martin, Jan [1 ]
Mistry, Rakesh [3 ]
Yonker, Marcy E. [1 ]
Press, Craig A. [4 ]
机构
[1] Univ Colorado, Dept Pediat, Sect Neurol, Anschutz Sch Med, Aurora, CO 80045 USA
[2] Univ Colorado, Dept Pediat, Anschutz Sch Med, Aurora, CO USA
[3] Univ Colorado, Sect Emergency Med, Anschutz Sch Med, Aurora, CO USA
[4] Univ Penn Perelman Sch Med, Dept Pediat & Neurol, Philadelphia, PA USA
关键词
INTRAVENOUS-SODIUM VALPROATE; MIGRAINE PROPHYLAXIS; DIVALPROEX SODIUM; SUMATRIPTAN; CHILDREN;
D O I
10.1212/CPJ.0000000000200170
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Objectives Pediatric headaches, including migraine, are a common reason for emergency department (ED) presentation. IV valproic acid (VPA) followed by oral VPA tapers are often used to abort pediatric headache and reduce recurrence, though limited data exist regarding this approach. This study evaluated the effectiveness of IV VPA and oral VPA tapers for the treatment of acute pediatric headaches in the ED in preventing return encounters.Methods This is a retrospective cohort study of patients aged 5-21 years presenting to a tertiary-care pediatric ED from 2010 to 2016 who received IV VPA for headache or migraine. Primary outcomes were ED disposition, percent pain reduction (initial vs 2-hour patient-reported pain score [10-point scale]), and return for acute headache treatment within 1 month.Results A total of 486 ED encounters were included with a median patient age of 15 years; most of them were females (76%, 369/486). Of available pain scores within 2 hours of IV VPA administration, 41% (173/425) had >= 50% pain reduction. Fifty-two percent (254/486) were discharged without additional treatment, 14% (69/486) were discharged after additional treatment, and 33% (163/486) were admitted to the hospital. Initial pain score, number of preceding home treatments, and number of preceding ED treatments were not associated with ED disposition. Oral VPA tapers were prescribed in 39% (94/253) of encounters when the patient was discharged after IV VPA. Oral VPA tapers produced a transient decrease in recurrence at 72 hours, which was no longer present at 1 week nor 1 month. There was no difference in the time to recurrence or total number of return visits within 1 month.Discussion IV VPA was efficacious in treating pediatric headaches evaluated in the ED, with nearly two-thirds of patients discharged home after administration. Oral VPA tapers did not reduce total headache recurrence nor time to recurrence. Given the limited benefit of oral VPA tapers, this practice should be re-examined.Classification of Evidence This study provides Class IV evidence that for children with headache seen in the ED, IV VPA reduces head pain and Class III evidence that following this with an oral VPA taper is of no benefit.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy
    Ferrara, Pietro
    Gatto, Antonio
    Blasi, Valeria
    Di Ruscio, Federica
    Battaglia, Domenica
    MINERVA PEDIATRICS, 2022, 74 (04): : 408 - 411
  • [32] The efficacy of valproic acid for retinitis pigmentosa patients
    Iraha, Satoshi
    Hirami, Yasuhiko
    Oota, Sachiko
    Mandai, Michiko
    Tanihara, Hidenobu
    Takahashi, Masayo
    Kurimoto, Yasuo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [33] The safety and efficacy of lamictal and valproic acid combination therapy in pediatric epilepsy patients
    Risner, M
    Messenheimer, J
    Giorgi, L
    Mullens, L
    Manasco, P
    NEUROLOGY, 1998, 50 (04) : A426 - A426
  • [34] Efficacy of valproic acid in the treatment of emotional disorders in children with abnormalities in EEG
    Gniot, B
    Dabkowski, M
    Buckowska, J
    Sciesinska, H
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S605 - S605
  • [35] Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient
    Akgun, Yamac
    Baykara, Yigit
    Langlie, Jake
    Van Truong, Lance
    Poveda, Julio
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (05): : 843 - 845
  • [36] Valproic Acid Induced Thrombocytopenia and Dysmegakaryopoiesis in a Pediatric Patient
    Langlie, J.
    Huberman, M.
    Akgun, Y.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 : S98 - S98
  • [37] Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid
    McNamara, Nancy A.
    Dang, Louis T.
    Sturza, Julie
    Ziobro, Julie M.
    Romanowski, Erin M. Fedak
    Smith, Garnett C.
    Joshi, Sucheta M.
    Leber, Steven M.
    Carlson, Martha
    Robertson, Patricia
    Shellhaas, Renee A.
    EPILEPSIA, 2020, 61 (08) : E85 - E89
  • [38] Valproic acid intoxication with suicide attempt in a pediatric patient
    Colak, Alkin
    Memis, Dilek
    Guzel, Ahmet
    Cerci, Hatice
    Gurkaynak, Betul
    PEDIATRICS INTERNATIONAL, 2011, 53 (05) : 781 - 783
  • [39] PHARMACOKINETICS OF VALPROIC ACID AFTER ORAL AND INTRAVENOUS ADMINISTRATION
    PERUCCA, E
    GATTI, G
    FRIGO, GM
    CREMA, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 5 (04) : 313 - 318
  • [40] Valproic acid in the treatment of malignant glioma in children
    Driever, Pablo Hernaiz
    Cinatl, Jindrich
    Wagner, Sabine
    Wolff, Johannes
    NEURO-ONCOLOGY, 2007, 9 (04) : 536 - 536